EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Allogeneic bone marrow transplantation for chronic myelogenous leukemia



Allogeneic bone marrow transplantation for chronic myelogenous leukemia



Lancet 1(8378): 665-668



In 117 patients with chronic myelogenous leukemia (CML) treatment with a combination of high-dose chemoradiotherapy plus transplantation of allogeneic bone-marrow from HLA-identical, mixed-lymphocyte-culture-identical siblings resulted in an actuarial probability of 3-yr survival of 63 .+-. 16% (95% confidence interval) for 39 patients transplanted in chronic phase; 36 .+-. 14% for 56 transplanted in accelerated phase; and 12 .+-. 15% for 22 transplanted during blast crisis. Irrespective of disease status at the time of transplantation, and in contrast to chemotherapy, a plateau-effect was observed in the survival curves starting 14 to 19 mo. after transplantation. The actuarial probability of recurrent or persistent leukemia at 3 yr was 7 .+-. 9% for patients transplanted in chronic phase, 41 .+-. 19% for accelerated phase and 41 .+-. 39% for blastic phase. All relapses occurred phase. All relapses occurred within 18 mo. of transplantation. Thus, long-term disease-free survival in CML can be achieved with bone-marrow transplantation. Best results were obtained in patients transplanted during chronic phase of the disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 004699093

Download citation: RISBibTeXText

DOI: 10.1016/0959-8049(93)91447-S



Related references

Comparison of the incidence of host-type hematopoiesis in patients with acute myelogenous leukemia and chronic myelogenous leukemia after sex mismatched, non-T-cell depleted, allogeneic bone marrow transplantation. Experimental Hematology (Charlottesville) 23(8): 854, 1995

Bone marrow reconstitution with normal autologous cells demonstrated by VNTR analysis after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Leukemia 11(12): 2213-2214, 1998

The graft versus leukemia (GVL) effect after allogeneic bone marrow transplantation for chronic myelogenous leukemia (CML). Leukemia & Lymphoma 11 Suppl 1: 221-226, 1993

Allogeneic bone marrow transplantation in children with chronic myelogenous leukemia. Journal of Pediatric Hematology/Oncology 24(3): 215-219, 2002

Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation. Journal of Clinical Oncology 5(7): 1033-1040, 1987

Activated allogeneic cell therapy for relapsed chronic myelogenous leukemia refractory to buffy coat transfusions post-allogeneic bone marrow transplantation. Bone Marrow Transplantation 18(6): 1153-1156, 1996

Timing of allogeneic bone marrow transplantation in chronic myelogenous leukemia patients. Japanese Journal of Clinical Hematology 27(12): 2261-2266, 1986

Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leukemia Research 33(9): 1291-1293, 2009

Allogeneic, syngeneic and autologous bone marrow transplantation for chronic myelogenous leukemia. Leukemia 7(7): 1084-1086, 1993

The reversal of myelofibrosis associated with chronic myelogenous leukemia after allogeneic bone marrow transplantation. Experimental Hematology 11(7): 681-685, 1983

Karyotype at relapse following allogeneic bone marrow transplantation for chronic myelogenous leukemia. Cancer Genetics & Cytogenetics. 61(2): 183-192, 1992

Allogeneic bone marrow transplantation as treatment for accelerating chronic myelogenous leukemia. Blood 63(1): 219-222, 1984

Allogeneic bone marrow transplantation for chronic myelogenous leukemia in genoa italy. Experimental Hematology (Charlottesville) 18(6): 665, 1990

5q- in a case of chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation. Haematologica 80(5): 437-439, 1995

Subdural hematoma during allogeneic bone marrow transplantation for chronic myelogenous leukemia. Acta Haematologica 88(2-3): 163-164, 1992